Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acalabrutinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK known ✓ | Q06187 | 19/20 | 1.00 |
| ▸ | TEC | P42680 | 2/20 | 1.00 |
| ▸ | TXK | P42681 | 2/20 | 1.00 |
| ▸ | BMX | P51813 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | BLK | P51451 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
| ▸ | ITK | Q08881 | 1/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 1/20 | 1.00 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 0.85 |
| ▸ | LYN | P07948 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acalabrutinib SCHEMBL30193365 | 1.00 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL17842601 | 1.00 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL31756796 | 1.00 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL29376537 | 1.00 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL14637370 | 1.00 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL18423036 | 0.98 | BTK (0.97) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL18423041 | 0.98 | BTK (0.97) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL18422158 | 0.98 | BTK (0.96) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL18422160 | 0.98 | BTK (0.96) | BTKTECTXKBMXEGFR | |
| SCHEMBL30468120 | 0.98 | BTK (0.96) | BTKTECTXKBMXEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5216 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-12630603-B2 | Chimeric antigen receptor T cell therapy | KITE PHARMA, INC. (US) | 2026-05-19 | — | — | US | claimed |
| CN-122055366-A | GCN2 and PERK kinase modulators and methods of use thereof | 德西费拉制药有限责任公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| US-20260124242-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2026-05-07 | — | — | US | claimed |
| WO-2026090557-A1 | SYSTEMS AND METHODS FOR PROCESSING ISM AND MCAS CLINICAL TRIAL DATA | TELIOS PHARMA INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20180208596-A1 | Solid Forms and Formulations of Imidazopyrazine Compound | ACERTA PHARMA B.V. (NL) | 2018-07-26 | — | — | US | claimed |
| US-20180179212-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2018-06-28 | — | — | US | claimed |
| US-9796721-B2 | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide | ACERTA PHARMA B.V. (NL) | 2017-10-24 | — | — | US | claimed |
| US-20170266191-A1 | Therapeutic Combination of PI3K Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2017-09-21 | — | — | US | claimed |
| US-9758524-B2 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2017-09-12 | — | — | US | claimed |
| US-20170029428-A1 | Solid Forms and Formulations of Imidazopyrazine Compound | ACERTA PHARMA B.V. (NL) | 2017-02-02 | — | — | US | claimed |
| US-20160151364-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2016-06-02 | — | — | US | claimed |
| US-9290504-B2 | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2016-03-22 | — | — | US | claimed |
| WO-2015057992-A1 | BTK INHIBITORS FOR HEMATOPOIETIC MOBILIZATION | IZUMI RAQUEL (US) | 2015-04-23 | — | — | WO | claimed |
| US-20140155385-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-06-05 | — | — | US | claimed |